Selective serotonin reuptake inhibitors (SSRIs) represent the most common treatment for major depression. However, their efficacy is variable and incomplete. In order to elucidate the cause of such incomplete efficacy, we explored the hypothesis positing that SSRIs may not affect mood per se but, by enhancing neural plasticity, render the individual more susceptible to the influence of the environment. Consequently, SSRI administration in a favorable environment promotes a reduction of symptoms, whereas in a stressful environment leads to a worse prognosis. To test such hypothesis, we exposed C57BL/6 mice to chronic stress in order to induce a depression-like phenotype and, subsequently, to fluoxetine treatment (21 days), while being exposed to either an enriched or a stressful condition. We measured the most commonly investigated molecular, cellular and behavioral endophenotypes of depression and SSRI outcome, including depression-like behavior, neurogenesis, brain-derived neurotrophic factor levels, hypothalamic-pituitary–adrenal axis activity and long-term potentiation. Results showed that, in line with our hypothesis, the endophenotypes investigated were affected by the treatment according to the quality of the living environment. In particular, mice treated with fluoxetine in an enriched condition overall improved their depression-like phenotype compared with controls, whereas those treated in a stressful condition showed a distinct worsening. Our findings suggest that the effects of SSRI on the depression- like phenotype is not determined by the drug per se but is induced by the drug and driven by the environment. These findings may be helpful to explain variable effects of SSRI found in clinical practice and to device strategies aimed at enhancing their efficacy by means of controlling environmental conditions.

Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment / Alboni, Silvia; van Dijk, R. M.; Poggini, Silvia; Milior, G.; Perrotta, M.; Drenth, T.; Brunello, Nicoletta; Wolfer, D. P.; Limatola, C.; Amrein, I.; Cirulli, F.; Maggi, L.; Branchi, I.. - In: MOLECULAR PSYCHIATRY. - ISSN 1359-4184. - ELETTRONICO. - 22:4(2017), pp. 552-561. [10.1038/mp.2015.142]

Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment

ALBONI, Silvia;BRUNELLO, Nicoletta;
2017

Abstract

Selective serotonin reuptake inhibitors (SSRIs) represent the most common treatment for major depression. However, their efficacy is variable and incomplete. In order to elucidate the cause of such incomplete efficacy, we explored the hypothesis positing that SSRIs may not affect mood per se but, by enhancing neural plasticity, render the individual more susceptible to the influence of the environment. Consequently, SSRI administration in a favorable environment promotes a reduction of symptoms, whereas in a stressful environment leads to a worse prognosis. To test such hypothesis, we exposed C57BL/6 mice to chronic stress in order to induce a depression-like phenotype and, subsequently, to fluoxetine treatment (21 days), while being exposed to either an enriched or a stressful condition. We measured the most commonly investigated molecular, cellular and behavioral endophenotypes of depression and SSRI outcome, including depression-like behavior, neurogenesis, brain-derived neurotrophic factor levels, hypothalamic-pituitary–adrenal axis activity and long-term potentiation. Results showed that, in line with our hypothesis, the endophenotypes investigated were affected by the treatment according to the quality of the living environment. In particular, mice treated with fluoxetine in an enriched condition overall improved their depression-like phenotype compared with controls, whereas those treated in a stressful condition showed a distinct worsening. Our findings suggest that the effects of SSRI on the depression- like phenotype is not determined by the drug per se but is induced by the drug and driven by the environment. These findings may be helpful to explain variable effects of SSRI found in clinical practice and to device strategies aimed at enhancing their efficacy by means of controlling environmental conditions.
2017
15-set-2015
22
4
552
561
Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment / Alboni, Silvia; van Dijk, R. M.; Poggini, Silvia; Milior, G.; Perrotta, M.; Drenth, T.; Brunello, Nicoletta; Wolfer, D. P.; Limatola, C.; Amrein, I.; Cirulli, F.; Maggi, L.; Branchi, I.. - In: MOLECULAR PSYCHIATRY. - ISSN 1359-4184. - ELETTRONICO. - 22:4(2017), pp. 552-561. [10.1038/mp.2015.142]
Alboni, Silvia; van Dijk, R. M.; Poggini, Silvia; Milior, G.; Perrotta, M.; Drenth, T.; Brunello, Nicoletta; Wolfer, D. P.; Limatola, C.; Amrein, I.; Cirulli, F.; Maggi, L.; Branchi, I.
File in questo prodotto:
File Dimensione Formato  
Alboni et al_ Mol Psy supplementary.pdf

Open access

Descrizione: Dati supplementari
Tipologia: Versione pubblicata dall'editore
Dimensione 977.78 kB
Formato Adobe PDF
977.78 kB Adobe PDF Visualizza/Apri
Alboni et al_Mol Psy_2017.pdf

Open access

Descrizione: Articolo principale
Tipologia: Versione pubblicata dall'editore
Dimensione 458.83 kB
Formato Adobe PDF
458.83 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1074817
Citazioni
  • ???jsp.display-item.citation.pmc??? 46
  • Scopus 133
  • ???jsp.display-item.citation.isi??? 106
social impact